Hørsholm, Denmark 28 May 2021
Gubra achieves strong growth results in its core CRO business.
New models in the Kidney Space and in 3D imaging well received by the market.
New AI/ML-based peptide target and drug discovery platform enables Gubra to deliver unbiased synthesis and identification of new complex peptides at unprecedented speed.
On a backdrop of COVID-19, Gubra closes 2020 with a thriving core business and a promising outlook for 2021. At the end of the year, gross profit amounted to MDKK 134.9M DKK. Pre-tax profits 20.3M DKK.
In 2020, Gubra achieved strong growth results in its core CRO business. A constant focus on efficiency and digitalization enabled Gubra to deliver an increased number of quality data and studies, even with a slight decrease in employees.
Investments into new disease models in the Kidney space and in 3D imaging have expanded Gubra’s services portfolio, and both offerings have been well received by the market.
New proprietary peptide target and drug discovery platform
Although Gubra received fewer milestone payments than the year before, this was expected. Eyes and expectations are on the company’s newest advanced technological and scientific venture: the launch of an innovative proprietary peptide target and drug discovery platform – streaMLine preDict and streaMLine conclude. With this new AI/ML-based platform inter-digitizing with the chemistry wet-labs, Gubra can deliver unbiased design, synthesis and characterization of peptides at unprecedented speed.
A constant focus on digitalization, artificial intelligence, machine learning and robotization are key drivers in Gubra’s science and continual business transformation.
CEO of Gubra Henrik Blou is satisfied with the results and confident about the years to come:
“From a financial perspective 2020 was a year in top 3 for Gubra. Science-wise, we are talking about a record year in terms of discovery, digitalization, robotization and innovation. We are very satisfied with our achievements in the digital and technological field. Combining this with our strong scientific profile and competencies the outlook is incredible.”
CSR report 2020: Gubra reveals new ways to reducing carbon emissions
Already last year, when Gubra launched its first CSR report, the company was able to show a negative carbon footprint. This was possible through responsible and deliberate climate-focused efforts. In its newest CSR report, Gubra reveals new ways to reducing its carbon footprint. For instance, by reducing commute transportation emissions via greener and healthier ways for employees to get to work. Also, Gubra has expanded its forest and nature project on the Danish island of Langeland.
Visit our CSR pages to read more and download Gubra CSR report 2020
Sofia Pitt Boserup
Lead Communication Partner
Gubra is a privately held biotech company since 2008, headquartered in Denmark. The company is a science and technology driven company with two primary areas of business: Preclinical contract research services (CRO) and proprietary early target and drug discovery programs. Gubra’s primary focus is within the metabolic space (obesity, diabetes, NASH, CKD, CVD and diabetic complications) adding to this fibrotic disease areas such as IPF and IBD. Gubra specializes in in vivo pharmacology, peptide chemistry, molecular pharmacology, histology, 3D imaging, stereology, NGS (next generation sequencing), bioinformatics and ex vivo assays. High quality, scientific excellence, advanced digitalization, speed and solid teamwork, are key company traits which have established Gubra as a highly professional and competent partner in the market. Learn more at www.gubra.dk
The post Annual results 2020: A thriving core business and razor-sharp biotech profile appeared first on Gubra.